ImageneBio Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023
Period Ending	Jun '25 Jun 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
Revenue	4.3	3.5	7.96
Revenue Growth (YoY)	-	-56.04%	-
Gross Profit	4.3	3.5	7.96
Selling, General & Admin	8.49	8.39	7.96
Research & Development	17.34	32.11	21.93
Operating Expenses	25.83	40.5	29.89
Operating Income	-21.53	-37	-21.93
Interest & Investment Income	0.08	0.37	1.19
Other Non Operating Income (Expenses)	0.12	0.07	-0.14
Pretax Income	-21.64	-36.56	-20.87
Income Tax Expense	0.01	0.01	0.28
Net Income	-21.66	-36.57	-21.15
Preferred Dividends & Other Adjustments	12.26	11.82	10.89
Net Income to Common	-33.91	-48.38	-32.04
Shares Outstanding (Basic)	392	391	321
Shares Outstanding (Diluted)	392	391	321
Shares Change (YoY)	-	21.97%	-
EPS (Basic)	-0.09	-0.12	-0.10
EPS (Diluted)	-0.09	-0.12	-0.10
Free Cash Flow	-25.31	-21.32	-18.54
Free Cash Flow Per Share	-0.07	-0.05	-0.06
Gross Margin	100.00%	100.00%	100.00%
Operating Margin	-500.72%	-1057.14%	-275.37%
Profit Margin	-788.70%	-1382.40%	-402.39%
Free Cash Flow Margin	-588.65%	-609.11%	-232.83%
EBITDA	-21.44	-35.86	-19.52
EBITDA Margin	-	-	-245.15%
D&A For EBITDA	0.1	1.14	2.41
EBIT	-21.53	-37	-21.93
EBIT Margin	-	-	-275.37%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q